EACS2023: 933 The value of assessing the primary level of CD4+ T cell and viral load of HIV RNA for modeling adverse risks during ART in persons living with HIV L. Shostakovych-Koretska , O. Sheveleva Dnipro State Medical University, Infectious Diseases, Dnipro, Ukraine General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: To study the value of the primary level and viral load of HIV RNA in connection with dynamics of clinical, immunological, and virological indicators of HIV status for modeling adverse risks during ART for individualization of the management of persons living with HIV. Method: A prospective cohort study included 450 persons living with HIV before ART initiation at the "Dnipro Regional AIDS Center " with 60 months follow-up. Survival Kaplan-Meier method was used in four groups of patients according to the initial level of CD4+ T cells and viral load, before and during ART. A proportional risk model evaluated the survival rate of patients on ART. Results: The cohort included 56.8% females (young, and middle-aged). Males were older, with lower CD4+ cells, and a higher viral load of HIV RNA (p=0.000). During 60 months: 63 died from HIV-related causes, 14 died from causes unrelated to HIV, 69 discontinued ART, and 304 continued ART. 10 main risk factors were selected: age over 40 years ( p < 0.003), male gender ( p < 0.007), clinical stage 4 of HIV ( p < 0.000), late ART initiation ( p < 0.000), the low initial level of CD4+ T cell ( p < 0.000), and after 6 months ( p < 0.000), high initial HIV viral load ( p < 0.001), co-infection viral hepatitis ( p < 0.02), low adherence to ART ( p < 0.000), The mathematical model may predict a high risk of mortality based on a total score of 10 indicators with a predictive accuracy of 89,7%; sensitivity 76,2%; specificity 94,0%. Conclusions: Thus, the prognostic model allows physicians to predict the existing risks at the time of ART. The model does not require complex calculations and has high prognostic effectiveness, which makes it possible to individualize the management of persons living with HIV. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 178 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=